Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Clin Cancer Res. 2013 Nov 15;20(1):246–252. doi: 10.1158/1078-0432.CCR-13-2098

Figure 3.

Figure 3

TGR profiling reveals specific patterns of antitumor activity across twelve phase 1 clinical trials (P values are computed from wilcoxon pairwise tests; n represent the number of samples with pairwise TGR information; only clinical trials with more than 7 patients were analyzed). Red, grey and green colors indicate progressive disease, stable disease and partial response as per RECIST criteria, respectively.